How confident are you in identifying von Hippel-Lindau disease early on?

Take our interactive Clinical Case Challenge to test your knowledge, get instant feedback, and access invaluable clinical practice tips. [PRIME]( [Unmasking von Hippel-Lindau (VHL) Disease: A Challenge in Clinical Recognition and Diagnosis]( [Take the CHALLENGE Today!]( Renal cell carcinoma, central nervous system (CNS) tumors, pheochromocytoma, retinal tumors, and pancreatic neuroendocrine tumors may all be identified individually, but when should you suspect von Hippel-Lindau (VHL) disease? VHL disease is a rare disorder characterized by the development of benign and malignant tumors and cysts in numerous organs/systems. The rarity of VHL disease and limited awareness of its clinical signs, symptoms, and diagnostic workup often results in delayed diagnosis. Given the need for early intervention, this delay contributes to less than optimal patient outcomes. Through this interactive Clinical Case Challenge, follow a real-world patient case, get instant feedback on answers to clinically relevant questions, and access downloadable evidence and relevant clinical practice tips. You can also see how you stack up against the knowledge of fellow healthcare providers! [0.25 CME/CE Credit Hour(s) | Clinical Case Challenge]( [For More Information Click Here]( [Take the CHALLENGE Today!]( Expert Faculty: Eric Jonasch, MD Speaker Professor of Medicine Department of Genitourinary Medical Oncology, Division of Cancer Medicine University of Texas, MD Anderson Cancer Center Director, VHL Clinical Center, MD Anderson Cancer Center Houston, Texas [Prime Education] PRIME Education, LLC 114 5th Ave, 14th Floor New York, NY 10011 (954) 718-6055 | [Contact us]( PRIME is a multi-disciplinary accredited provider of continuing medical education. [Unsubscribe from future emails](lst=NL_Prime_Specialty_Newsletters) | [Contact us]( | [COVID-19 Resource Center](